Vitamin K Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, mix, and dual demand pools

• Brevintel analysis values the vitamin K market at USD 1.07 billion in 2025 ($1.07B), expanding from USD 1.14 billion in 2026 to USD 2.4 billion in 2035 ($2.4B) at an 8.5% CAGR.
• A parallel estimate places 2025 revenue at USD 1,315.82 million, rising to USD 2,370.01 million in 2035, so both the 8.5% card CAGR and the 8.46% narrative CAGR are retained.
• DSM-Firmenich led with over 10% market share in 2025; DSM-Firmenich, BASF SE, Kappa Bioscience, Lonza, and Glanbia collectively held 35%.
• Hospital and protocol use of vitamin K1 for coagulation factors VII, IX, and X sits beside extrahepatic K2 demand tied to osteocalcin, matrix Gla protein, bone mineralization, and vascular calcification.
• Cardiovascular disease caused an estimated 19.8 million deaths globally in 2022, while fragility fractures affect up to 37 million people annually, giving both streams durable clinical relevance.
• Late vitamin K deficiency bleeding occurs at an estimated median rate of 35 per 100,000 live births without prophylaxis and is more frequent in lower-income countries.
• North America generated USD 499.82 million in 2024 and is projected to reach USD 945.24 million by 2035 at an 8.13% CAGR, supported by birth-dose protocols and institutional phytonadione use.
• U.S. dietary-supplement sales reached USD 69.3 billion in 2024, providing a broad retail base for bone-health and combination products that include vitamin K.

Clinical protocols versus preventive spending

• K1 demand is sustained by anticoagulation management, deficiency treatment, and neonatal prophylaxis, while K2 captures spending tied to aging, fracture prevention, and nutrient combinations.
• The resulting mix makes vitamin K less cyclical than a single-purpose wellness ingredient, while still exposing premium K2 suppliers to formulation and claim-substantiation risk.
• Evidence linking vitamin K-dependent proteins to skeletal and vascular biology broadens product development, but it does not automatically convert into permitted therapeutic claims.
• Suppliers with documented ingredients and the ability to support food, supplement, and pharmaceutical customers are better placed to monetize that gap than brands relying on generic vitamin claims.

Market Dynamics

Demand drivers

• Osteocalcin requires vitamin K-dependent carboxylation for effective bone mineralization, while matrix Gla protein is relevant to inhibition of vascular calcification, creating product-specific preventive-health rationales.
• Europe had 32 million people over age 50 living with osteoporosis in 2019, and its population aged 65 years and older reached 21.6% in 2023, supporting recurring demand where supplements are accessible.
• That demographic base also raises the evidence threshold for suppliers seeking to differentiate premium K2 combinations from broad vitamin-mineral products.
• In the United States, vitamin and mineral supplements are used by a large majority of adults, and bone health remains among the leading reasons consumers purchase supplements.
• Relative to MK-4, MK-7 remains detectable in circulation for longer and can be effective at microgram doses, supporting smaller-dose consumer products and sustained premium positioning.
• Microencapsulation can protect MK-7 when it is formulated with minerals and moisture-sensitive ingredients, enabling the K2, vitamin D, and mineral combinations that dominate bone-health innovation.
• A study of nanoencapsulated MK-7 reported higher exposure and peak concentration than a conventional powder formulation, shifting value toward isomeric purity, stability, and delivery-system performance.
• The American Academy of Pediatrics recommends intramuscular vitamin K at birth, creating recurring institutional K1 demand that is less dependent on consumer awareness or retail-channel performance.

Constraints

• Injectable phytonadione is managed as a drug product, while dietary supplements and foods follow separate ingredient, manufacturing, labeling, and health-claim rules, limiting rapid cross-category launches.
• European requirements are particularly consequential for K2 because a clinical evidence base does not automatically authorize a consumer-facing health claim or skip country-level adaptation.
• Vitamin K generally has no established tolerable upper intake level, but changes in intake can interfere with warfarin dose management, making anticoagulation patients a poor fit for unsupervised K supplements.
• Intravenous phytonadione carries a boxed warning for severe hypersensitivity reactions, including anaphylaxis, particularly with rapid administration, so hospitals reserve parenteral vitamin K for justified indications.
• Brevintel analysis indicates that the 8.46% market CAGR is supported by protocol-driven K1 demand and discretionary K2 supplementation, but neither stream is frictionless.
• The same regulatory separation that limits rapid launches protects established suppliers with pharmaceutical-quality systems, claim substantiation, and long-standing customer qualification.
• Research into roles beyond coagulation, including ferroptosis and cellular metabolism, remains option value rather than a near-term commercial indication base.
• Commercial success depends on segment-specific communication: hospital suppliers must prioritize safe administration and supply continuity, while K2 brands must not imply that preventive positioning overrides anticoagulation management.

Segmentation Analysis

Type

• Vitamin K1 led the market with a 68.40% share in 2025, equivalent to approximately USD 900.0 million, reflecting coagulation management, parenteral nutrition, and neonatal prophylaxis.
• DSM-Firmenich produces vitamin K1 in oily and dry forms, while BASF supplies vitamin K1 for dietary supplements, functional foods, and premixes.
• K1 is projected to expand at approximately 8.3%, supported by its embedded role in healthcare delivery rather than premium consumer positioning.
• Vitamin K2 represented 31.60% of 2025 revenue, or approximately USD 415.8 million, with MK-7 the principal commercial growth platform because of its longer circulating profile.
• Fermentation capability, all-trans isomer quality, and encapsulation technologies determine whether suppliers can convert that scientific distinction into stable finished products.
• Gnosis by Lesaffre and Kappa Bioscience, now part of Balchem, exemplify this higher-specification K2 ingredient segment.

Application

• Prothrombin deficiency was the largest application at 25.84% of 2025 revenue, or approximately USD 340.0 million, anchored in hospital and outpatient management of coagulation abnormalities.
• Vitamin K deficiency bleeding followed at 23.07%, or approximately USD 303.6 million; infants who do not receive a vitamin K injection at birth are substantially more likely to develop late VKDB.
• Those two segments are tied to clinical protocol adoption and public-health coverage rather than conventional consumer purchasing cycles.
• Osteoporosis accounted for 20.76% of the market, or approximately USD 273.2 million, and is the most important bridge between clinical evidence and nutraceutical K2 growth.
• Dermal applications accounted for 10.18%, or approximately USD 134.0 million, and remain concentrated in topical products associated with post-procedure bruising and erythema.
• Other applications represented 19.20%, or approximately USD 252.6 million, including fortified-food and emerging uses.
• Vitamin K-dependent clotting factor deficiency represented 0.96%, or approximately USD 12.6 million; its small revenue base reflects rare-disease status but still requires standardized specialist products.

Route of administration

• Oral products held 69.74% of 2025 revenue, or approximately USD 917.7 million, because pills, powders, and liquids accommodate self-directed supplementation and non-urgent outpatient use.
• The oral route also favors K2 products designed for repeated use and combination formulations, including oil-based formats that can aid absorption of a fat-soluble vitamin.
• Parenteral products accounted for 22.74%, or approximately USD 299.2 million, with value linked to neonatal prophylaxis, acute care, and hospital coagulopathy management rather than consumer demand.
• Topical products represented 7.52%, or approximately USD 99.0 million, and are tied to dermal and medical-aesthetic use cases with distinct specialty channels.
• The three routes therefore have distinct purchasing centers: consumers and retailers for oral products, hospital formularies for parenteral products, and specialty dermal channels for topical products.

Distribution channel

• Offline channels retained 64.40% of market revenue in 2025, or approximately USD 847.4 million, and are projected to grow at approximately 8.6%.
• Pharmacy stores remain central to both prescription-adjacent K1 use and professionally recommended supplement purchases, while specialty stores support premium K2 combinations.
• Hypermarkets and supermarkets provide broad access to mainstream vitamin products and help keep offline channels larger than digital-only routes.
• Online channels accounted for 35.60%, or approximately USD 468.4 million, and are projected to grow at approximately 8.2%.
• Digital channels allow ingredient and dosage-form distinctions to be explained in greater depth, which is particularly useful for MK-7, isomer quality, and multi-nutrient formulations.
• Online growth also increases exposure to inconsistent product claims, making recognized quality credentials and transparent formulation information more commercially valuable.
• Brevintel analysis finds the growth premium in the K2-osteoporosis-oral nexus, while K1, prothrombin deficiency, VKDB, and parenteral products supply the volume stability beneath it.
• In 2025, oral products represented USD 917.7 million, giving premium K2 ingredients a much wider commercial outlet than hospital-only formats.

Regional Outlook

North America and Europe

• North America held 41.10% of global revenue in 2025, equivalent to USD 535.95 million, and remains the principal mature-channel pool for both K1 and K2.
• The region was valued at USD 438.62 million in 2022, USD 467.57 million in 2023, and USD 499.82 million in 2024, and is projected to reach USD 945.24 million by 2035 at an 8.13% CAGR.
• The U.S. represented 90.30% of North American revenue in 2025, while Canada accounted for 9.70%.
• Osteoporosis affects more than 10 million U.S. adults, most of whom are women, while mass retail, pharmacies, and direct-to-consumer channels provide broad supplement access.
• Canada's natural-health-product framework requires evidence-based product licensing, which raises compliance demands but favors suppliers able to document ingredient quality and permitted claims.
• Europe represented 28.10% of global revenue in 2025, or approximately USD 369.7 million, spanning Germany, the UK, France, Spain, Italy, and the Netherlands.
• The region's aging population and osteoporosis treatment gaps sustain demand, but suppliers must translate scientific support into claims and registrations that comply with country and EU-level rules.
• DSM-Firmenich, BASF, and Gnosis by Lesaffre maintain European production or commercial infrastructure, rewarding quality-led competition over simple expansion of low-cost K2 supply.

Asia Pacific, Latin America, and Middle East and Africa

• Asia Pacific accounted for 22.40% of global revenue in 2025, or approximately USD 294.7 million, and is projected to record the fastest regional CAGR at 8.9%.
• Japan has a long clinical and commercial history with vitamin K2, including pharmaceutical use of MK-4, and its natto tradition has contributed to familiarity with menaquinones.
• China and India provide the largest volume opportunity as aging, fracture burden, healthcare access, and supplement consumption expand, but local registration, channel, and pricing strategies are required.
• Australia's established supplement and neonatal-care systems provide a more mature regional market, while South Korea offers a receptive premium-consumer base.
• Latin America represented 5.90% of 2025 global revenue, or approximately USD 77.6 million, with Brazil, Mexico, and Argentina as the principal markets.
• Projected hip-fracture burden and under-recognition of vertebral fractures indicate unmet skeletal-health need, but affordability constrains rapid adoption of premium combination supplements.
• The Middle East and Africa accounted for 2.50% of global revenue in 2025, or approximately USD 32.9 million, with Saudi Arabia, the UAE, and South Africa the most accessible markets.
• Bone-health positioning can benefit from regional vitamin D concerns and vitamin D-K combinations, but affordability, regulatory timelines, and uneven hospital access limit near-term scale.

Competitive Landscape

Structure and positioning

• The market is moderately concentrated among ingredient suppliers and more fragmented among finished-product brands.
• The top five companies DSM-Firmenich, BASF SE, Kappa Bioscience, Lonza, and Glanbia held an estimated combined share of approximately 35% in 2025, with DSM-Firmenich at an estimated 10% share.
• DSM-Firmenich supplies vitamin K1 in oily and dry forms across food, beverage, dietary-supplement, and pharmaceutical applications, while BASF SE supplies vitamin K1 for supplement, functional-food, and premix customers.
• Kappa Bioscience's K2VITAL platform emphasizes all-trans MK-7 and double-microencapsulation technology, while Gnosis by Lesaffre markets fermentation-derived MenaQ7 ingredients with a clinical-evidence base.
• Lonza and Glanbia extend the field through nutrition-ingredient, blending, and manufacturing capabilities rather than a single vitamin K form.
• Amphastar Pharmaceuticals and Pfizer participate in institutional vitamin K supply, where procurement qualification and reliable availability are central.
• Nature's Bounty, Nature Made, NOW Foods, Solgar, and Country Life compete through retail reach, brand trust, formulation breadth, and direct online access, while Livealth Biopharma adds an India-based manufacturing presence.
• K1 competition centers on quality, regulatory compliance, and continuity of supply; K2 competition centers on all-trans purity, combination-product stability, bioavailability, and supportable health positioning.

Integrated producers

• DSM-Firmenich
• BASF SE
• Lonza
• Glanbia

Specialty suppliers

• Kappa Bioscience
• Gnosis by Lesaffre
• Amphastar Pharmaceuticals
• Pfizer
• Nature's Bounty
• Nature Made
• NOW Foods
• Solgar
• Country Life
• Livealth Biopharma